FTI $13.93 -1.0653%
MPACU $7.97 0%
UTSL $29.40 0.4441%
IFRX $4.98 1.6327%
PEG.L $7.50 0%
AVTX $2.45 2.0833%
0XWD.L $1.79 0%
0578.HK $0.05 0%
0MEL.L $2.25 -0.2217%
CLWD.L $6.54 0%
ALLT $2.73 -1.7986%
ABUS $2.56 -0.1953%
CCV-UN $10.10 0%
IUSG $89.45 -0.6222%
MUC $10.73 -0.2001%
DBX $22.02 1.3812%
8189.HK $0.10 1.0101%
0IFK.L $9.29 -3.4527%
FTII $10.54 0%
IVEG $20.08 0.008%
1626.HK $3.21 0%
RCFA $10.51 0%
DRW $22.88 26.8988%
EXR $151.80 -0.508%
DECAW $0.06 0%
ALUM.L $2.97 -0.2683%
LBE.L $19.25 -1.2821%
PRSR.L $85.30 -0.2339%
1371.HK $0.68 1.4925%
XSW $115.16 -1.3888%
CS $0.84 -0.4013%
FMIVU $10.23 0%
VCYT $23.42 -0.6785%
EWZ $29.71 0.4905%
CCON $53.03 0%
0RTK.L $82.60 0%
0159.HK $0.16 1.25%
ALTVO.PA $30.00 0%
XPON $5.60 -9.3851%
BTOU.SI $0.14 -0.6993%
8262.HK $0.18 0%
PLG $1.52 -3.8734%
RFG $180.39 -0.8763%
CSGP $74.89 -0.1134%
MTL $2.25 0%
SRP.L $150.20 1.0087%
ONTO $88.10 -0.8051%
2126.HK $3.29 -4.0816%
0N5I.L $129.00 0.1618%
HYZD $20.39 0.0982%
1172.HK $0.04 -4.6512%
PSB $187.44 0%
RCHG $10.12 0%
1235.HK $0.18 0%
1617.HK $0.10 -3.0612%
0VGI.L $31.29 -6.4115%
PFMT $2.33 2.8761%
SBS $10.64 8.5204%
VRRM $17.23 -1.0626%
PCPC-UN $25.07 0%
SCYX $2.76 0.3891%
8148.HK $0.08 -10.989%
0948.HK $0.95 0%
MAKX $31.96 0%
BWFG $21.88 0.0457%
NOG.L $10.05 0%
1971.HK $1.92 0%
GUAR3.SA $4.43 -2.4229%
INSI $15.54 -0.1607%
ALIDS.PA $150.00 -0.6623%
EVGN $0.67 4.7244%
SNDL $1.69 3.681%
MASS $7.53 -0.1326%
0OQX.L $15.70 0%
0LFS.L $64.70 -0.1367%
HEWJ $30.41 1.1643%
KSMTU $10.75 0%
BTTR $0.42 -0.0839%
NVT $41.00 -0.6061%
BTAQU $10.03 0%
BJ $70.61 -2.0594%
1832.HK $0.83 0%
0HT4.L $87.04 0.0749%
CSSG.L $49.91 4.4184%
XUTC.L $65.95 -0.3702%
CPIX $1.67 -2.907%
PRP.L $67.00 0%
EXFO $6.25 0%
PHP.L $104.20 -0.5725%
8107.HK $1.21 3.4188%
PRDS $1.89 1.6129%
AATG.L $74.00 2.069%
2121.HK $20.00 -2.6764%
0968.HK $7.62 -3.2995%
2197.HK $1.63 -4.6784%
BHV $10.65 0.5333%
DSACU $9.08 0%
1153.HK $0.28 0%
GRCY $11.24 -0.7067%
STWO $8.21 0%
Eng
Логотип
Eng
Лого

Lysogene S.A. LYS.PA

$0.28

На 18:01, 12 мая 2023

Ранг: 2

Ранг - это оценка кредитоспособности корпорации.

Ключевые показатели

  • Marketcap

    4946116.00000000

  • week52high

    1.74

  • week52low

    0.23

  • Revenue

    3731000

  • P/E TTM

    0

  • Beta

    0.92404500

  • EPS

    -0.44000000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    13 окт 2022 г. в 10:59

Описание компании

Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек